Recent outbreaks of hantavirus, including a 2026 cruise ship cluster with eight confirmed and suspected Andes virus cases, have prompted renewed research funding and preclinical work on DNA and mRNA candidates targeting the Gn-Gc spike complex. However, no vaccine has advanced beyond early-stage trials or preclinical testing as of May 2026, with experts estimating three to five years before phase 2 or 3 studies could begin and additional years for regulatory approval. Historical patterns show sporadic transmission limits large-scale efficacy trials, while funding gaps and the absence of an Operation Warp Speed-style initiative further extend timelines. Trader consensus at 90.5% for no approval this year reflects these barriers, though accelerated government support or breakthrough data could narrow the gap before year-end.